STOCK TITAN

Stereotaxis, Inc. - $STXS STOCK NEWS

Welcome to our dedicated page for Stereotaxis news (Ticker: $STXS), a resource for investors and traders seeking the latest updates and insights on Stereotaxis stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Stereotaxis's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Stereotaxis's position in the market.

Rhea-AI Summary
Stereotaxis reports 28% revenue growth in Q2 2023 and highlights strategic collaborations and innovation advancements
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
13.38%
Tags
-
Rhea-AI Summary
Stereotaxis announces successful treatment of first patients using Abbott's EnSite X EP System with Stereotaxis' Robotic Magnetic Navigation System. The integration of these technologies provides highly detailed diagnostic information and precise therapy delivery.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.03%
Tags
none
-
Rhea-AI Summary
Stereotaxis will release its financial results for the 2023 second quarter on August 10, 2023. The company will host a conference call and webcast to discuss the results and corporate developments.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.67%
Tags
conferences earnings
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-20.3%
Tags
none
-
Rhea-AI Summary
Stereotaxis CEO David Fischel will participate in Craig-Hallum’s 20th Annual Institutional Investor Conference and will be available for one-on-one meetings with attendees. Fischel is excited to share Stereotaxis' technology, clinical value, and growth strategy with investors.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.47%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.17%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
33.14%
Tags
none
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.7%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.55%
Tags
conferences earnings
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.68%
Tags
none
Stereotaxis, Inc.

NYSE:STXS

STXS Rankings

STXS Stock Data

163.63M
56.29M
15.87%
47.5%
1.13%
Surgical and Medical Instrument Manufacturing
Manufacturing
Link
United States of America
ST.LOUIS

About STXS

stereotaxis is the global leader in innovative robotic technologies designed to enhance the treatment of arrhythmias and perform endovascular procedures. its mission is the discovery, development and delivery of robotic systems, instruments, and information solutions for the interventional laboratory. these innovations help physicians provide unsurpassed patient care with robotic precision and safety, improved lab efficiency and productivity, and enhanced integration of procedural information. over 100 issued patents support the stereotaxis platform. the core components of stereotaxis’ systems have received regulatory clearance in the united states, european union, japan, canada, china, and elsewhere. for more information, please visit www.stereotaxis.com.